A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

NCT07222670 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

1100

Enrollment

INDUSTRY

Sponsor class

Conditions

Viral Respiratory Infection
Viral Respiratory Illnesses

Interventions

DRUG: INNA-051
OTHER: Placebo

Sponsor

ENA Respiratory Pty Ltd